secwatch.observer — SEC 8-K summary
======================================

Issuer:     Catheter Precision, Inc. (VTAK)
CIK:        0001716621
Form:       8-K
Filed at:   2022-07-08T23:59:59+00:00
Accession:  0001564590-22-025521
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ra Medical appoints CEO as interim CFO; gets FDA clearance but won't sell DABRA 2.0
--------------------------------------------------------------------------------

- Jonathan Will McGuire, current CEO, appointed interim CFO effective July 8, 2022; no extra compensation.
- FDA 510(k) clearance granted for DABRA 2.0 catheter on July 5, 2022.
- Company states it has no plans to commercialize the DABRA 2.0 catheter.
- Board continues strategic alternatives review; in June 2022 cut workforce by ~65% to preserve capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716621/000156459022025521/0001564590-22-025521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716621/000156459022025521/rmed-8k_20220708.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-025521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer